EAIs are the current recommended first-line ...
Should FDA approval of Zohydro ER be revoked?
Yes, extended-release hydrocodone has high potential for abuse.
No, the drug is intended to help patients for whom other pain treatments are ineffective.
It should stay on the market but with the strictest prescription controls possible.